A carregar...
Publicação
Contribuição para desenvolvimento de suplemento alimentar a partir de excedentes de produção e comercialização de agrião
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.87 MB | Adobe PDF |
Orientador(es)
Resumo(s)
A Esclerose Lateral Amiotrófica (ELA) é uma doença neurodegenerativa caracterizada pela perda progressiva de neurónios motores, com consequente aumento da rigidez muscular que constringe a capacidade do movimento e da respiração por parte do doente.
Apesar dos progressos realizados no âmbito da investigação da ELA e do contributo dos mesmos para a identificação dos genes associados a esta doença, abrindo porta à descoberta de novos alvos terapêuticos, muitas questões permanecem em aberto no que se refere ao processo patológico que institui a ELA. Assomando-se à gravidade desta doença que permanece sem cura, é escasso o arsenal terapêutico disponível para a gestão desta patologia. À data, apenas um fármaco com capacidade de retardar o agravamento clínico se encontram aprovados: Riluzol®.
No decorrer da doença, a perda de apetite comumente verificada nos doentes conduz a um consumo restrito de alimentos que se torna insuficiente para suprir as suas necessidades energéticas. Adicionalmente, a ELA encontra-se associada a um estado de hipermetabolismo levando a que os portadores despendam calorias mais rapidamente do que os não-portadores. Como resultado, frequentemente doentes da ELA possuem um peso inferior às suas necessidades.
A ausência de tratamentos efetivos desperta um interesse crescente nas propriedades neuroprotetoras dos compostos bioativos presentes em certos alimentos, nomeadamente em frutas e vegetais. O agrião é um vegetal classificado como superalimento, dados os seus inúmeros benefícios para a saúde e por conter grandes quantidades de fitoquímicos que poderão auxiliar nos mecanismos de neuroprotecção na ELA.
Com a realização deste projecto pretende-se obter uma base para o desenvolvimento da produção de um suplemento alimentar à base de extrato de agrião. Será revisada a doença, passando pelas necessidades para a colocação da suplementação no mercado europeu, até à sua formulação líquida contendo os compostos sulforafano, isotiocianato de feniletilo (PEITC), luteina/zeaxantina e vitamina K, presentes no vegetal.
The Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons, with the consequent increase of muscle stiffness that constricts the patient's ability to move and breathe. Recent advances in ALS research had lead to the discovery of new therapeutic targets through the successful identification of genes that contribute to the development of ALS. Nevertheless, many questions concerning the pathological process of ALS remain open. The lack of therapeutic options available for ALS management is one of the biggest concerns in this pathology. Only one approved drug is effective in delaying clinical worsening: Riluzol®. During the progress of the disease, loss of appetite is commonly observed in patients, which leads to a restricted food intake that becomes insufficient to fulfil its energy needs. In addition, ALS is associated with a state of hypermetabolism, which becomes insufficient to satisfy its energy needs. As a result, ALS diseased are often underweight, since they spend more calories than healthy people. The absence of effective treatments has increased the interest in the neuroprotective properties of bioactive compounds present in certain foods, especially fruits and vegetables. Watercress is classified as superfood, given their many benefits for health and the large quantities of potential neuroprotective phytochemicals that it contains. This project intends to provide a basis for the development of the production of a watercress-based food supplement. The disease will be analysed, going over dietary suplements state in the European market. Its liquid formulation contains sulforaphane, phenylethyl isothiocyanate (PEITC) lutein/zeaxanthin and vitamin K.
The Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons, with the consequent increase of muscle stiffness that constricts the patient's ability to move and breathe. Recent advances in ALS research had lead to the discovery of new therapeutic targets through the successful identification of genes that contribute to the development of ALS. Nevertheless, many questions concerning the pathological process of ALS remain open. The lack of therapeutic options available for ALS management is one of the biggest concerns in this pathology. Only one approved drug is effective in delaying clinical worsening: Riluzol®. During the progress of the disease, loss of appetite is commonly observed in patients, which leads to a restricted food intake that becomes insufficient to fulfil its energy needs. In addition, ALS is associated with a state of hypermetabolism, which becomes insufficient to satisfy its energy needs. As a result, ALS diseased are often underweight, since they spend more calories than healthy people. The absence of effective treatments has increased the interest in the neuroprotective properties of bioactive compounds present in certain foods, especially fruits and vegetables. Watercress is classified as superfood, given their many benefits for health and the large quantities of potential neuroprotective phytochemicals that it contains. This project intends to provide a basis for the development of the production of a watercress-based food supplement. The disease will be analysed, going over dietary suplements state in the European market. Its liquid formulation contains sulforaphane, phenylethyl isothiocyanate (PEITC) lutein/zeaxanthin and vitamin K.
Descrição
Tese de mestrado, Ciências Biofarmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2018
Palavras-chave
Watercress Bioactive compounds Amyotrophic lateral sclerosis Neuroprotection Supplemention Teses de mestrado - 2018